Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells

Combining Type I Interferons and 5-Aza-2′-Deoxycitidine to Improve Anti-Tumor Response against Melanoma

(2017) Valeria Lucarini et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer

(2016) Hyun-Jeong Ko et al.   ARCHIVES OF PHARMACAL RESEARCH

DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer

(2016) Krista P. Terracina et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tolerance and immune suppression in the tumor microenvironment

(2016) Suzanne Ostrand-Rosenberg   CELLULAR IMMUNOLOGY

Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia

(2016) Yu Jing et al.   Oncotarget

Improving cancer immunotherapy by targeting the STATe of MDSCs

(2016) Nienke de Haas et al.   OncoImmunology

Regulatory T Cell DNA Methyltransferase Inhibition Accelerates Resolution of Lung Inflammation

(2015) Benjamin D. Singer et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Decitabine: a promising epi-immunotherapeutic agent in solid tumors

(2015) Xiang Li et al.   Expert Review of Clinical Immunology

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

IFN Regulatory Factor 8 Represses GM-CSF Expression in T Cells To Affect Myeloid Cell Lineage Differentiation

(2015) Amy V. Paschall et al.   JOURNAL OF IMMUNOLOGY

Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model

(2015) L. Wang et al.   Cancer Immunology Research

Myeloid-derived suppressor cell heterogeneity in human cancers

(2014) Samantha Solito et al.   Annals of the New York Academy of Sciences

Clinical development of demethylating agents in hematology

(2014) Shyamala C. Navada et al.   JOURNAL OF CLINICAL INVESTIGATION

Unknown

(2014) Michael Chan et al.   MOLECULAR MEDICINE

The Role of Myeloid-Derived Suppressor Cells in Immune Ontogeny

(2014) Soren Gantt et al.   Frontiers in Immunology

Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly

(2013) Paolo Serafini   IMMUNOLOGIC RESEARCH

Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis

(2013) Jeremy D. Waight et al.   JOURNAL OF CLINICAL INVESTIGATION

Exosomes from Myeloid-Derived Suppressor Cells Carry Biologically Active Proteins

(2013) Meghan Burke et al.   JOURNAL OF PROTEOME RESEARCH

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses

(2013) Li-Xin Wang et al.   PLoS One

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

(2013) Yushi Yao et al.   PLoS One

Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine

(2011) Mengyong Yan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing

(2011) Lei Bao et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway

(2011) Veerauo V Konkankit et al.   Journal of Translational Medicine

Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines

(2011) Sabine Hagemann et al.   PLoS One

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia

(2010) J. Choi et al.   BLOOD

Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13

(2010) S. L. Highfill et al.   BLOOD

Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling

(2010) Hua Xiong et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

(2010) Maika Almstedt et al.   LEUKEMIA RESEARCH

Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine

(2009) Irina Daurkin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells

(2008) P. Serafini et al.   CANCER RESEARCH